There is one clinical trial.
This study is being done to learn whether a new method to prevent rejection between the donor immune system and the patient's body is effective.
T351I mutation). --- T351I ---
Description: The intervention will be considered unpromising if the rate of GVHD is greater than 40% and promising if the rate is 20% or less.Measure: the number of incidences of grade 3-4 acute GVHD Time: 2 years